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ABSTRACT Gerrardanthus macrorhizus (GM) caudex, is tradiধonally used in cancer therapy by the Tetun people in Belu Dis-
trict, East Nusa Tenggara Province, Indonesia, where it is known as “akar batu”. This study aimed to explore the cytotoxic
effects of G. macrorhizus caudex aqueous extract, as well as its combinaধon with doxorubicin, on MCF-7 cells. Also invesধ-
gated were the possible mechanisms of interacধon through cell cycle progression and apoptosis inducধon. Single treatments
of 5–320 µg/mL of the extract showedmorphological alteraধons inMCF-7 cells, but did not show any cytotoxic effect. Com-
bining the extract with doxorubicin resulted in a synergisধc cytotoxic effect. Doxorubicin concentraধons equivalent to 1/12,
1/8, and 1/5 fold of the IC50 combined with 20 µg/mL decreased viability to 48%. We then explored the combinaধon effect
of doxorubicin 0.4 µM with GM 5 and 20 µg/mL using a flow cytometer. A low concentraধon of the extract (5 µg/mL)
combined with 0.4 µM of doxorubicin resulted in slight cell cycle modulaধon by G1, G2M arrested and apoptosis inducধon.
The combinaধon of doxorubicin and a higher concentraধon of the extract (20 µg/mL) did not show cell cycle modulaধon,
and led to necrosis. Therefore, G. macrorhizus caudex at low concentraধons has the potenধal to be developed further as a
co-chemotherapeuধc agent.
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1. Introducধon
Plants have been used as primary source of medicines
for thousands of years. Secondary metabolites in plants
have been the most promising and potential source of drug
discovery leads (Dias et al. 2012). Various pharmaco-
logical target including cancer becomes important leads
of medicinal plant drug discovery. Recently, plant sec-
ondary metabolites and their derivatives have been ad-
justed in most clinical application treatment against can-
cer.The field of chemoprevention also played an impor-
tant role in cancer treatment. Chemoprevention is one
of strategy towards combating cancer by administration
of synthetic or natural compounds to reverse or suppress
carcinogenesis. Chemopreventive agents perform through
various actions interfering initiation, promotion, and pro-
gression of carcinogenesis (Balunas and Kinghorn 2005).
Cancer is of a significant health concern and a leading
cause of death worldwide. The major contributor of can-
cer is strongly related to family history, involvement of
lifestyle, and other environmental factors with a defective
gene (Kamil and Kamil 2015). In many countries, cancer
is the second leading cause of death following cardiovas-
cular diseases (Ma and Yu 2006). Breast cancer remains
a major challenge, the most frequently diagnosed and the
leading cause of cancer death among women. It accounts
25% of the total cancer cases (1.68million) and 15% of the
cancer deaths (520,000) worldwide. Adjuvant systemic
therapy has used widespread and contributed to diminish
breast cancer mortality rates.(Anampa et al. 2015). Dox-
orubicin is one of the most commonly used chemothera-
peutic for many types of cancers including breast cancer.
Doxorubicin inhibits topoisomerase I and II, and also in-
tercalates into DNA to interfere with its uncoiling, finally
inducing programmed cell death (apoptosis). The greatest
risk of doxorubicin is cardiotoxicity, causing the enlarge-
ment of cardiomyocytes. Thus, doxorubucin administra-
tion must be dose-limited (Tacar et al. 2013). The reduc-
tion of doxorubicin dose might be achieved through the
combination with chemopreventive agent.
The combination of natural chemopreventive agent
and conventional chemotherapy is one of promising ap-
plication in cancer treatment. Rational combination is ex-
pected to provide simultaneous action to create more sus-
ceptible cancer cells and to exploit the chances for bet-
ter efficacy, decreased toxicity, and reduced drug resis-
tance development (Foucquier and Guedj 2015). Our un-
published study in 2012 (National Research on Medicinal
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Plant and Jamu, RISTOJA) resulted some plants used for
traditional cancer treatment. One of those plants isGerrar-
danhus macrorhizus Harv. ex Benth. & Hook.f. which
belongs to Cucurbitaceae family, and characterized with
unique caudex above the ground. So, commonly people
use it as decorative plant. The caudex is used by tradi-
tional healers in Tetun ethnic for cancer therapy in Belu
Distric, Nusa Tenggara Timur Province, Indonesia. The
anticancer activity of this plant have not been explored so
far. Therefore, this present study was aimed to explore the
cytotoxic effect ofG. macrorhizus caudex aqueous extract
in MCF-7 human breast cancer cell line, and its combina-
tion effect with doxorubicin. We also investigated the pos-
sible mechanisms of interaction between doxorubicin and
the extract through cell cycle progression and apoptosis
induction by flow cytometer.
2. Materials and methods
2.1. Materials and extracࣅon
G. macrorhizus (GM) caudex was obtained from Belu
Distric, Nusa Tenggara Timur Province, Indonesia. The
caudex was sliced, dried in 40°C, grinded, and boiled with
aquadest 90°C for 10 min, then filtered. The supernatant
was dried in oven 40°C for ±3 d to obtain dried extract.
The extract 10.0mg and doxorubicin 5.0mgwas dissolved
in 100 µL DMSO (Sigma), and freshly diluted in culture
medium in several concentration before used. The exact
concentration were mentioned in a part of MTT assay.
2.2. Cell culture
MCF-7 cell lines were obtained from ATCC, and main-
tained in Laboratory of Molecular Biology, the Medici-
nal Plant and Traditional Medicine Research and Develop-
ment Centre, the Ministry of Health, Tawangmangu, Jawa
Tengah, Indonesia.
2.3. Morphological observaࣅon and cytotoxic MTT as-
say
The MCF-7 cells were cultured in 10 mm dish with
Minimum Essential Medium (MEM Gibco) containing
10% fetal bovine serum/FBS (Gibco), 1% penicillin-
streptomycin (Gibco), and incubated in CO2 incubator
5% at 37°C.When the cells were already confluent, the
medium was discarded, washed with phosphate buffer
saline (PBS Sigma) 1x, and added trypsin EDTA 0.25% to
detach cells. Harvested cells were counted using a haemo-
cytometer. Approximately 1x104 MCF-7 cells/well were
seeded in 96-well plates and incubated for 48 h. Cells
were treated with increasing concentration of GM extract
(10, 20, 40, 80, 160, and 320 µg/mL) or doxorubicin (0.3,
0.5, 1.1, 2.2, 4.4, 8.8, and 11 µM) for 24 h. Morphologi-
cal observation of the cells were done under inverted mi-
croscope, and documented using digital camera (Canon
Ixus). Then, culturedmediumwas removed and cells were
washed with PBS (Sigma). MTT 0.5 mg/mL in medium
were added into each well and incubated for 3–4 h. MTT
reaction was stopped by the addition of SDS 10% in HCl
0.01 N, and incubated overnight in the dark room. The ab-
sorbance was measured using ELISA reader at λ 595 nm
(Biorad). Each treatment were carried out in triplicate, and
the absorbance data are provided as percentage of viabil-
ity compared to control cells without treatment (untreated,
only culturedmedium added). The combination assay was
done using the same method. The concentration used in
combination treatment were below the IC50 value of sin-
gle doxorubicin and GM extract. In this research, we com-
binedGM5.0, 7.5, 15.0, and 20.0 µg/mLwith doxorubicin
0.4, 0.6, and 1.3 µM. Each concentration was combined
with others (12 combinations) and performed in triplicate.
2.4. Cell cycle result and apoptosis inducࣅon by flow
cytometry assay
Approximately 5x105 MCF-7 cells/well were cultured in
6 well plate and incubated for 48 h. Cells were then
treated with G. macrorhizus and doxorubicin, either alone
or combination for 24 h. Cells were harvested with trypsin
EDTA, washed in phosphate-buffered saline (PBS), and
centrifuged 500 rpm for 5 min. For apoptosis induction,
cells then incubated with annexin-V-FITC and propidium
iodide (BD Pharmingen) for 15 min in the dark, and ana-
lyzed using BD Accuri C6 Flowcytometer. To determine
cell cycle distribution, cells were fixed with cold ethanol
70% for 30 min, washed with PBS, and centrifuged 500
rpm for 5 min. Cells were then resuspended in PBS con-
taining 40 μg/mL propidium iodide (Sigma), 20 μg/mL
RNAse (Roche) and 0.1%TritonX-114 (Sigma) for 15min
in the dark, and then subjected to BD Accuri C6 flowcy-
tometer for further analysis.
2.5. Data analysis
To calculate the IC50 value from single cytotoxicity assay,
we plotted linear regression of concentration and percent-
TABLE 1 Interpretaধon of CI value represenধng potency of combinaধonal applicaধon (Reynolds and Maurer 2005).
CI Interpretaধon CI Interpretaধon
< 0.10 Very strong synergist 0.90–1.10 Closely addiধve
0.10–0.30 Strongly synergist 1.10–1.45 Middle antagonist
0.30–0.70 Synergist 1.45–3.30 Antagonist
0.70–0.90 Middle synergist >3.30 Strongly antagonist
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age of cells viability using MS Excel 2013. Combination
treatment was evaluated by calculating the Combination
Index (CI) value with the following formula:
CI = D1/Dx1+ D2/Dx2 (1)
D1 and D2 described the concentrations used in combina-
tional treatment, while Dx1 and Dx2 are single treatment
concentration giving the same response as D1 and D2, re-
spectively. Interpretation of CI value was represented as
listed in Table 1 (Reynolds and Maurer 2005). The data
obtained from flow cytometer was analyzed using BD Ac-
curi C6 software, and evaluated with the Student t-Test
Paired Two Samples for Means. In all analyses, p<0.05
was considered to be statistically significant.
3. Results
3.1. Cell growth inhibitory effect by single treatment of
G. macrorhizus and doxorubicin
Cytotoxic activity of GM caudex aqueous extract onMCF-
7 cells were done byMTT assay. The cells treated with sin-
gle extract in all concentrations (10–320 µg/mL) showed
morphological changes similar to cell death configuration.
They were detected to become losing their shapes, form-
ing wider intercell spaces, getting shrinkage, and appeared
in visibly different as compared to medium control cells
(Figure 1a). However, when MTT was added to the cells,
formazan crystal were formed just like in untreated cells
(Figure 1b). The MTT should be converted into purple
colored formazan by viable cells with active metabolism
which involves reaction with NADH or similar reducing
molecules. Thus, formazan formation presents as a use-
ful and appropriate marker of only viable cells (Riss et al.
2016). In this research, the analysis of formazan color ab-
sorbance vs cell viability showed no difference effect with
untreated cells (Figure 1c). It means that cells treated with
GM extract, although showing a morphological changes,
they were remained viable and still having ability to con-
vert MTT into formazan.
Meanwhile, cells treated with doxorubicin for 24 h re-
sulted in growth inhibition and cell death in a dose and
time dependent manner, as shown in Figure 2. The IC50
determination of doxorubicin by linear regression was 5
µM (Figure 2).
Based on the MTT assay results of single doxorubicin
and GM extract, we were then assessed the combination
effect of GM extract and doxorubicin in some series con-
centration on MCF-7 cells.
3.2. Combined effect of G. macrorhizus extract with
doxorubicin on MCF-7 cell viability
The combination assay was done using concentration be-
low the IC50 of doxorubicin (0.4, 0.6, and 1.3 µM), and
the concentration of GM that already caused morpholog-
ical changes (5.0, 7.5, 15.0, and 20.0 µg/mL). Increasing
concentration of G. macrorhizus extract and doxorubicin
in combination was followed by a decreasing cell viability,
and resulted in the CI value less than 1, as seen in Figure 3a
and 3b. It indicated that combinational treatment of GM
extract and doxorubicin exhibited a synergistic inhibitory
effect on MCF-7 cells viability rather than additive or an-
tagonistic. Strongly synergist was achieved at the lowest
and middle concentration of doxorubicin (0.4 µM and 0.6
µM) each combined with the middle and highest concen-
tration of the extract (10 and 20 µg/mL) successively.
3.3. Cell cycle progression and apoptosis inducࣅon
The combined effect of doxorubicin and the extract on
cell growth inhibition could be developed as the result of
cell cycle modulation and apoptosis induction. To investi-
gate its synergistic mechanism, we further explored MCF-
7 cell cycle progression and cell death using a flow cytome-
GM 10 µg/mL GM 160 µg/mL Untreated
GM 10 µg/mL GM 160 µg/mL Untreated
(a)
(b)
(c)
FIGURE 1Morphological changes of MCF-7 cells treated by GM 10 and 160 µg/mL for 24 h compared to untreated cells. (a) MCF-7 cells
before MTT addiধon; and (b) formazan crystal formaধon formed by the cells ađer MTT assay, both taken under inverted microscope with
200x magnificaধon; (c) the viability vs GM concentraধon. The MTT assay was performed in triplicate, data represented as mean ± SD of
percentage of cell viability. GM: G. macrorhizus extract
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FIGURE 2 The effect of doxorubicin for 24 h on MCF-7 cells via-
bility. The MTT assay was performed in triplicate, data are repre-
sented as mean ± SD of percentage of cell viability.
ter. Two combinations were selected, doxorubicin 0.4 μM
- extract 5 μg/mL for middle synergist (CI 0.7) and dox-
orubicin 0.4 μM - extract 20 μg/mL for strong synergist
(CI 0.1). Cell cycle analysis of the treatment is shown in
Figure 4. Single treatment of doxorubicin 0.4 μM slightly
induced G2/M arrested (33.5%), while extract 5 μg/mL
slightly induced G1 arrested (61.1%), and their combi-
nation induced both G1 (58.4%) and G2/M (30.9%) ar-
rested, compared to untreated cells 27.6% and 52.9% suc-
cessively. Single treatment of extract 20 μg/mL combined
with doxorubicin 0.4 μM both significantly increased cell
population in subG1 compared to untreated cells.
To understand cell death mechanism in subG1 pop-
ulation, whether synergistic combination was mediated
through apoptosis, we stained treated cells with propidium
iodide-annexin and subjected to flow cytometer as seen in
Figure 5. The results showed the apoptotic population was
significantly increased inMCF-7 cells treated by combina-
tion of doxorubicin 0.4 μM with extract 5 μg/mL (7.6%)
and also by doxorubicin 0.4 μM with extract 20 μg/mL
(8.2%). Both was compared with control cells (1.8%) and
any single treatment (doxorubicin (2.7%), extract 5 μg/mL
(2.1%), extract 20 μg/mL (2.6%)).
4. Discussion
Doxorubicin is one of the most active chemotherapy agent
and widely used for breast cancer treatment. Its applica-
tion in chemotherapy is often limited due to cardiotoxicity
risk and resistance progression (Zeichner et al. 2016). The
development of doxorubicin resistance in breast cancer is
multifactorial process, mainly associated with wide and
diverse expression of drug-resistance genes. AbuHam-
mad and Zihlif (2013), using doxorubicin resistant MCF-7
breast cancer cells proved an up-regulation of many phase
I/II metabolizing genes and drug efflux pump genes and
many other changes in genes responsible for cell cycle,
apoptosis and DNA repair (AbuHammad and Zihlif 2013).
The combination with a natural chemopreventive agent
is one of promising strategy to improve doxorubicin anti-
(a)
(b)
FIGURE3The synergisধc inhibitory effect ofG.macrorhizus extract
in combinaধon with doxorubicin on MCF-7 cell. (a) cytotoxic com-
binaধon assay. Cells were treated with series combinaধon for 24
h, inhibitory effect was determined with MTT assay. The assay
was performed in triplicate, data are represented as mean ± SD
of percentage of cell viability (the SD values ranges 0.2–6.9). (b)
Combinaধon Index (CI) resulted by means of cell viability in each
treatment. All of the CI value were <1, indicaধng synergism effect
between the combinaধon. GM: G. macrorhizus extract.
cancer effectiveness and reduce its toxicity (Ko and Moon
2015). Therefore, we investigated the modulatory effect
of G. macrorhizus caudex aqueous extract on the doxoru-
bicin cytotoxicity, cell cycle and apoptosis in MCF-7 hu-
man breast cancer cell line.
In this study, G. macrorhizus caudex aqueous extract
was first evaluated for cytotoxicity effect to MCF-7 cells.
The MTT assay revealed that the extract did not influence
viability and cytotoxic effect. However, the apparent cell
shrinkage was clearly observed on MCF-7 cells treated
with the extract in all concentration (10–320 µg/mL). Cell
shrinkage characterized by smaller size, dense cytoplasm
and tightly packed organelles, is identified as the early
sign of morphological changes during apoptosis process
(Elmore 2007). Apoptosis, one of cell death design, is
an ordered and orchestrated cellular process that occurs in
physiological condition and pathological ofmany diseases.
Apoptosis evasion plays a crucial role in carcinogenesis,
therefore it is created as a popular target for cancer treat-
ment strategy (Wong 2011). Based on the morphological
alteration, we suggest that the extract might have ability
to improve sensitivity of MCF-7 cells to doxorubicin.
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FIGURE 4 Treatment of G. macrorhizus extract, doxorubicin and their combinaধon modulated MCF-7 cell cycles. Cells were treated for 24 h
and stained with PI reagent, each sample was subjected to flow cytometer.GM: G. macrorhizus extract.
The MTT assay of doxorubicin single treatment de-
creased cell viability with the IC50 value of 5 µM. We
further demonstrated MTT assay combination for doxoru-
bicin and the extract to obtain CI value. The CI is widely
accepted as the simplest possible way to express pharma-
cologic drug interaction for quantifying synergism or an-
tagonism. Synergism interaction will be very useful to
treat the dreadful diseases, such as cancer. The main gains
are the achievement of synergistic therapeutic effect, re-
duction of dose and toxicity, and also minimize or delay
drug resistance (Chou 2010). In this research, we used CI
values to evaluate the combination effect of doxorubicin
and extract on the percentage of viability of MCF-7 cells.
Based on the CI values, the extract sensitized MCF-7 cells
and enhanced doxorubicin cytotoxicity by less than 1, at
any concentration level. This result was indicating that
the combination obviously exerted synergistic inhibitory
effect on MCF-7 viability. The smallest concentration
of doxorubicin (0.4 µM equal to 0.08 fold of IC50) com-
bined with 20 µg/mL of extract decreased MCF-7 viabil-
ity to 48.4%. Therefore, the extract may lead to reduc-
ing of doxorubicin dose therapy and furthermore minimiz-
ing its cardio toxicity risk. In this study, G. macrorhizus
caudex aqueous extract potentially enhanced proliferation
inhibitory effect of doxorubicin on MCF-7 cells.
The most vital characteristic of cancer cells involves
the ability to sustain chronic proliferation by deregulating
of growth-promoting signals through the cell growth and
division cycle (Hanahan and Weinberg 2011). The cell
cycle is a tidy and tightly regulated mechanism by which
cell divide, involving four phases namely G1, S (synthe-
sis), G2 and M (mitosis) (Deep and Agarwal 2008). The
basic processes of cell cycle development implicate the
complex interaction of various proteins in a systematic
and coordinated manner (Shah and Schwartz 2001). The
aberrant cell cycle progression plays a crucial role in can-
cer cell growth, thus targeting the cell cycle have been re-
garded as an ideal cancer treatment (Deep and Agarwal
2008). Doxorubicin modulates cell cycle through G1 and
G2 phase arrest, as the result of its interaction with topoi-
somerase II mediated DNA damage (Lal et al. 2010). As
our result, single doxorubicin 0.4 µM slightly induced cell
accumulation at G1 and G2/M phase by 2.6% and 5.9%
respectively but did not lead cell death, compared to un-
treated MCF-7 cells. The extract 5 µg/mL alone increased
G1 while 20 µg/mL increased subG1 phase accumulation.
The combination of doxorubicin with the extract 5 µg/ml
enhanced cell accumulation at G1 andG2/M, compared by
single doxorubicin. Furthermore, doxorubicin combined
with the extract 20 µg/mL increased cell death in subG1
by 31.8%, compared by each single treatment.
The cell cycle arrest depicted a survival mechanism
for the cancer cell to repair its own damaged DNA. The
disruption of cell cycle checkpoints by specific agent be-
fore completing DNA repair, can activate the apoptotic
pathway leading to cell death (Schwartz and Shah 2005)
Doxorubicin caused apoptosis in cancer cells by early ac-
tivation of p53 followed by caspase-3 activation and DNA
fragmentation (Wang et al. 2004). In our study, single
treatment of doxorubicin 0.4 µM and the extract 5 and 20
µg/mL had no significant effect to apoptosis induction. In-
terestingly, the extract 20 µg/mL caused significant necro-
sis on MCF-7 cells. This was not in line with the result of
cytotoxic assay. MCF-7 cells treated with the extract had
still interacted with MTT to form formazan crystal. There-
fore, this finding need further research to establish the ac-
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(a) (b)
FIGURE 5 Treatment of doxorubicin and extract combinaধon significantly induced apoptosis in MCF-7 cell. Cells were treated for 24 h and
stained with annexin V-PI, each sample was subjected to flow cytometer in triplicate. (a) The diagrams are divided into four area, which
showed distribuধon profiles of living cells (boħom-leđ), early apoptoধc (boħom-right), late apoptosis (upper-right), necrosis (upper-leđ) in
various indicated treatment. (b) Staধsধcal analysis results for apoptosis inducধon for each treatment.
tual evidence occured in cells treated with high concentra-
tion of the extract. However, the combination of doxoru-
bicin with both of the extract (5 and 20 µg/mL) increased
apoptotic and necrotic cell induction, compared by each
single treatment.
Cell cycle regulation and apoptosis induction plays a
critical role in malignant transformation and in the devel-
opment chemotherapy resistance. These have led to the
development of anticancer therapeutics that target the mo-
tors of the cell cycle specifically the cyclin dependent ki-
nases (CDKs). The abrogation of cell cycle checkpoints
at critical time by a CDKs inhibitor is expected to make
the tumor cell susceptible to apoptosis. The application
of CDKs inhibitor as single agents is intended to target
the errors of cell cycle regulation to attain cancer cells
spesific cytotoxicity.Currently, these agents are combined
with conventional chemotherapy to overcome cell cycle
mediated drug resistance and enhance cytotoxic efficacy
(Schwartz and Shah 2005).
5. Conclusions
Based on these findings, G. macrorhizus caudex aqueous
extract in all concentration used in this research increased
and revealed synergistic effect on doxorubicin cytotoxi-
city. Doxorubicin concentration which equivalent with
1/12, 1/8, and 1/5 fold of IC50, combined with 20 µg/mL
decreased viability to 48%. Low concentration of the ex-
tract (5 µg/mL) combined with 0.4 µM doxorubicin re-
sulted slight cell cycle modulation by G1, G2M arrested
and apoptosis induction. The combination with higher
concentration (20 µg/mL of the extract) did not show cell
cycle modulation, and leading to necrosis. Therefore,
the extract at low concentration performs potential natu-
ral source to be developed further as co-chemotherapeutic
agent. Thus, further research is needed to find the molec-
ular mechanism underlying the anticancer effect of G.
macrorhizus caudex.
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